Bristol-Myers Squibb Company (BMY) said Wednesday its Opdivo drug significantly increased the overall survival of patients with resectable non-small cell lung cancer combined with chemotherapy, compared to those that underwent chemotherapy only.
This was from the company's analysis of the results of its phase 3 Checkmate -816 study, which was a key secondary endpoint of the study. It also builds on the successful primary endpoints of the study with regard to event-free survival and pathological complete response.
Opdivo is a programmed death-1 immune checkpoint inhibitor that is designed to use the body's own immune system to help restore anti-tumor immune response.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。